290363-59-6

Basic information

• Product Name: (R)-C-(1-BENZYL-PIPERIDIN-3-YL)-METHYLAMINE
• Synonyms: (R)-C-(1-BENZYL-PIPERIDIN-3-YL)-METHYLAMINE;C-[1-BENZYL-PIPERIDIN-(R)-3-YL]-METHYLAMINE;(R)-(1-Benzylpiperidin-3-yl)MethanaMine
• CAS NO: 290363-59-6
• Molecular Formula: C13H20N2
• Molecular Weight: 204.31
• Mol File: 290363-59-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 303.1°C at 760 mmHg
• Flash Point: 126.4°C
• Appearance: /
• Density: 1.018g/cm³
• Vapor Pressure: 0.00095mmHg at 25°C
• Refractive Index: 1.551
• CAS DataBase Reference: (R)-C-(1-BENZYL-PIPERIDIN-3-YL)-METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-C-(1-BENZYL-PIPERIDIN-3-YL)-METHYLAMINE(290363-59-6)
• EPA Substance Registry System: (R)-C-(1-BENZYL-PIPERIDIN-3-YL)-METHYLAMINE(290363-59-6)

Safety Data

• Hazardous Substances Data: 290363-59-6(Hazardous Substances Data)

Usage

General Description

(R)-C-(1-benzyl-piperidin-3-yl)-methylamine is a chemical compound with a molecular formula C16H22N2. It is a chiral amine, meaning it has a non-superimposable mirror image, and is commonly used as a building block in organic synthesis. (R)-C-(1-BENZYL-PIPERIDIN-3-YL)-METHYLAMINE is often employed in the production of pharmaceuticals and is a key intermediate in the synthesis of various drugs. Its unique structure and properties make it versatile for use in the development of new medications and other valuable compounds.

InChI:InChI=1/C13H20N2/c14-9-13-7-4-8-15(11-13)10-12-5-2-1-3-6-12/h1-3,5-6,13H,4,7-11,14H2/t13-/m1/s1

Upstream product

• 100-39-0 benzyl bromide 
• 1026661-43-7 (S)-piperidine-3-carboxylic acid amide hydrochloride 
• 23099-21-0 3-Aminomethylpiperidine 
• 100-52-7 benzaldehyde 
• 1378312-69-6 (±)-1-benzoylpiperidine-3-carboxamide 
• 98-88-4 benzoyl chloride 
• 4138-26-5 nipecotamide 
• 22977-34-0 N-(pyridin-3-ylmethyl)acetamide 
• 100-44-7 benzyl chloride 
• 170701-83-4 N-(1-benzylpiperidin-3-yl)methylacetamide 
• 124257-64-3 3-<(acetylamino)methyl>-1-benzyltetrahydropyridin-3-ene 

Downstream Products

• 220031-61-8 tert-butyl (1-benzylpiperidin-3-yl)methylcarbamate 
• 1016167-99-9 (S)-1-piperidin-3-ylmethylcarbamic acid tert-butyl ester 
• 142643-29-6 tert-butyl (piperidin-3-ylmethyl)carbamate 

Relevant articles and documents

Design, synthesis, and in vitro evaluation of hydroxybenzimidazole-donepezil analogues as multitarget-directed ligands for the treatment of Alzheimer's disease

A series of multi-target-directed ligands (MTDLs), obtained by attachment of a hydroxyphenylbenzimidazole (BIM) unit to donepezil (DNP) active mimetic moiety (benzylpiperidine /-piperazine) was designed, synthesized, and evaluated as potential anti-Alzheimer's disease (AD) drugs in terms of biological activity (inhibition of acetylcholinesterase (AChE) and β-amyloid (Aβ) aggregation), metal chelation, and neuroprotection capacity. Among the DNP-BIM hybrids studied herein, the structural isomerization did not significantly improve the biological properties, while some substitutions, namely fluorine atom in each moiety or the methoxy group in the benzyl ring, evidenced higher cholinergic AChE activity. All the compounds are able to chelate Cu and Zn metal ions through their bidentate BIM moieties, but compound 5, containing a three-dentate chelating unit, is the strongest Cu(II) chelator. Concerning the viability on neuroblastoma cells, compounds 9 and 10 displayed the highest reduction of Aβ-induced cell toxicity. In silico calculations of some pharmacokinetic descriptors indicate that all the compounds but the nitro derivatives have good potential oral-bioavailability. Overall, it can be concluded that most of the studied DNP-BIM conjugates showed quite good anti-AD properties, therefore deserving to be considered in further studies with the aim of understanding and treating AD.

Preparation and structure confirmation new methods of (S)-3-Boc-aminomethylpiperidine

The invention discloses preparation and structure confirmation of (S)-3-Boc-aminomethylpiperidine. A compound 5 is obtained by benzylation of a compound 1, reduction of a carbonyl group, protection ofan amino group, and catalytic hydrogenation; then the compound 5 is subjected to derivation to obtain a crystal; the crystal is subjected to diffraction test and analyzed to obtain that the compound5 is the (S)-3-Boc-aminomethylpiperidine, and the optical rotation is -8.98, which further proves that the method for preparing the compound 5 is feasible. According to the preparation method, the cheap and easily available chiral raw material compound 1 is used without using a resolving agent, and the advantages in yield and cost are realized; the product is tested by derivatization and diffraction way to determine the correct configuration, and the preparation and confirmation methods form a system, thereby facilitating industrial production and realizing a broad application prospect.

DISUBSTITUTED PIPERIDINE DERIVATIVES AS BUTYRYLCHOLINESTERASE INHIBITORS FOR USE IN THE TREATMENT OF ALZHEIMER

This invention relates to new inhibitors of butyrylcholinesterase with general formulas I and II, where substituents are described in patent description. Compounds can be in the form of pure enantiomers or as racemic mixtures, or in the form of pharmaceutically acceptable salts. The present invention relates to the use of these inhibitors for the treatment of Alzheimer's disease and other forms of dementia.